Learn from world KOLs in vaccines on the latest in technology platforms, global health, pandemic preparedness, therapeutic vaccines, zoonotic diseases and development of the whole life cycle. Attend one event for all of your vaccine knowledge needs.
With a footfall of 2500+ attendees, exhibitors will get to speak directly to their target market, expand sales leads, strengthen and establish their brand and close deals with customers on-site.
Get access to our dedicated event app (live 3 weeks before the event), see all of our 2500+ attendees and set up 1-2-1 meetings to maximise your ROI in attending the congress.
Meet start-ups at the leading vaccine congress. Meet new companies that can help your business or investors that can take you to the next level.
Host or participate in our pre-congress workshops where we deep dive into topics including new technologies, biothreats, alternative vaccine delivery routes, and global equity with all stakeholders.
Be part of a NEW format – our working groups. Replacing roundtables, these sessions are intimate discussions and one of the best ways to find out what your target audience wants.
Meet up and coming academics and spin out organisations at the poster zone where you will be presented with unpublished research that is changing the field of vaccine development. Applications open soon.
The media zone will be bustling with all of the biggest names in the vaccine world. Witness live interviews and use our zone to announce press releases and social media outreach to maximise your presence.
Join 2,500 attendees at the Europe's largest vaccine event.
This is your best opportunity in 2025 to network with leading vaccine experts.
Johannes is a veterinary scientist and regularly invited speaker at international workshops or conferences. After a career of 13 years as scientist in the field of veterinary parasitology and epidemiology at Ghent University (1st veterinary faculty in Shanghai Ranking Index 2017-2019), and 2 years...
I have an interest in understanding the immunological mechanisms that underlie the success or failure of vaccines developed to induce T-cell responses in livestock species. This has predominantly focused on Theileria parva but I also have interests in other major pathogens including Mycobacterium...
Dimitri Diavatopoulos is Assistant Professor at the Laboratory of Medical Immunology and is affiliated with the Radboud Center for Infectious Diseases. Dr. Diavatopoulos studied Bioprocess Engineering at Wageningen University, after which he obtained his PhD at Utrecht University, where he started...
Mark A. Emalfarb is the founder of Dyadic, and currently serves as the Chief Executive Officer and a member of the Board of Directors of the Company. He has been a member of Dyadic’s board of directors and has previously served as its Chairman from October 2004 until April 2007 and from June 2008...
Prof. Carlos A. Guzmán (MD, PhD) is head of the department Vaccinology and Applied Microbiology at the Helmholtz Centre for Infection Research and also APL professor at the Hannover Medical School.He studied Medicine at the National University of Rosario and received his specialization in Medical...
Parasites cause some of the most deadly diseases to affect humans. Malaria is the most devastating of these, and is responsible for hundreds of millions of cases each year, with hundreds of thousands of deaths. In order to survive within our bodies, parasites must interact with the molecules of our ...
Dr. Infante is leading the development of a new class of vaccines to prevent antibiotic-resistant infections globally. The technology enables development of truly global vaccines, able to target at-risk populations in both high- and low-income countries, and has been developed with the support of...
Alasdair King qualified as a veterinary surgeon from Glasgow University in 1990. After 11 years in mixed practice he joined Intervet UK as livestock veterinary advisor. Amongst other roles in the UK, he took on responsibility for company pharmacovigilance as the National PV Manager, and developed ...
Darren holds a PhD in microbiology from Trinity College Dublin, where he also did his BA in microbiology. He spent a three year post-doc in the Jenner Institute at the University of Oxford developing vaccines against infectious diseases. He is an experienced team and project leader in both start-up ...
Stanley has over 20 years of experience in vaccine development, biologics, and cell/gene therapy, with a strong background in GMP biosafety, GLP technical operations, and commercial strategy. He holds a Bachelor of Science from Pennsylvania State University and an MBA from Alvernia University. His...
Dr. Milla Runsala earned her Doctorate from the University of Turku, where she researched immune responses. She currently serves as a Business Development Manager, focusing on exploring new opportunities for sustained drug therapies using Silica Matrix drug delivery technology. Recently, DelSiTech...
Co-founder and Chief Executive Officer of Scandinavian Biopharma. Björn is former Chief Executive Officer of UniTech Pharma AB (2010-2011), Chief Business Officer of Crucell (2006-2009), a Dutch former listed company with facilities in the Netherlands, Switzerland and USA specializing in vaccines...
Y. Tony Yang, ScD, LLM, MPH, is an endowed professor (with tenure) in health policy and Associate Dean for Health Policy and Population Science at George Washington University School of Nursing. He also holds a joint appointment at the Milken Institute School of Public Health in the Department of...
Ana joined the NATO Innovation Fund as a Senior Associate and is excited about the potential of technology to drive growth and societal welfare. In particular she will help build NIF’s strategy and portfolio for biotech, biosecurity, synthetic biology and human enhancement. She will also be taking...
Marco Cavaleri is the Head of Public Health Threats at the European Medicines Agency (EMA). He leads EMA activities on emerging pathogens, vaccines, and antimicrobial resistance, and previously chaired the EMA’s COVID-19 Taskforce. With extensive experience in both industry and regulatory roles, he ...
Ingrid de Visser - Kamerling (1975) graduated in Medical Biology from Leiden University in 1998. She subsequently worked at CHDR as a project leader and PhD student. She obtained her PhD from Leiden University in 2003 and became a registered clinical pharmacologist in 2005. From 2004 to 2007, she...
Dr. Kyle Doolan leads cross-functional teams in molecular biology, protein engineering and virology that perform experiments for operations and research and development. Kyle has been instrumental in enhancing the performance of Integral Molecular’s technologies and is an inventor on two of...
Dr. Christina K. Go earned her Ph.D. in Biomedical Sciences from the Lewis Katz School of Medicine at Temple University studying membrane protein interactions in T cell activation. Following her dissertation, she completed a research fellowship at the University of Pennsylvania in immunology ...
Dr Bassam Hallis has over 25 years experience in scientific research including 15 years in regulated activities including vaccine evaluation, release/stability and clinical trial serology. He has extensive experience in assay development and validation including cell based and functional assays as...
Lennard is an accomplished Oxford University cancer physician and national senior advisor for the cancer vaccine advance in the UK, and chief medical officer at the Ellison Institute of Technology. He is a research scene setter with a successful track record in delivering strategic national health...
Elise Pepermans obtained her PhD in Biochemistry in the Pasteur Institut in Paris. During her post-doc in the Center for Proteomics (University of Antwerp/Flemish Institut for Technological Research) she developed an optimized workflow for advanced immunopeptidomics. Since March 2023, she is one of ...
A veterinarian by training, after completing my PhD at The Pirbright Institute in 1993 I became Head of the International FMD Vaccine Bank and held the position for 4 years. I moved to Pfizer AH in Sandwich, England in 1997 and eventually became Director of Biologicals Research for Europe, Africa...
Tyler Sandberg is a scientist holding a PhD in vaccine immunology from the Karolinska Institute and a master’s degree in immunology and infection biology from Uppsala University.His doctoral research involved conducting several vaccine studies to examine human immune responses to various flavivirus ...
Dr. Veterinary Medicine, virologist, global networking in human and animal health, vaccines and diagnostics, global disease control, one health, public affairs with EU, WHO, Asian and African authorities and experienced in vaccine translational development.Achievements in brief: Discovery of H1N1...
Fabrizio Chiodo studies adaptive and innate responses of non-mammalian glyco-conjugates, mostly in the context of vaccines and host-pathogen interactions. During his PhD (defended in 2013, San Sebastian, Spain), working on a new generation of vaccines technology he had a long stay at the Amsterdam...
Join our mailing list to receive exclusive content and offers.
By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.